ClinicalTrials.gg

Program

GnRH Antagonist SHR7280

Also written as “SHR7280 tablets”, “SHR7280” and “SHR7280;Ganirelix Acetate Injection simulant”.

In Jiangsu HengRui Medicine's pipeline, GnRH. Its studies are mostly in Endometriosis · Leiomyoma · Prostatic Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Jun 16, 202210 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine101 open or runningphase 3since Jun 16, 2022May 21, 2020none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR7280, phase 4, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 21, 2020First study: phase 2 study in EndometriosisFirst studyNCT04417972 · 179 enrolled · China
  2. Aug 31, 2020Phase 1 study in Healthy SubjectsNCT04554043 · 118 enrolled · China
  3. Jul 29, 2021Phase 1 study in Hormone Sensitive Prostate CancerNCT04995042 · 12 enrolled · China
  4. Sep 29, 2021Phase 2 study in Female Subjects Undergoing COH in ART to Prevent Early OvulationNCT05082233 · 85 enrolled · China
  5. Jun 16, 2022Phase 3 study in Uterine Fibroids With MenorrhagiaNCT05442827 · 357 planned · China
  6. May 11, 2023Phase 1 study in EndometriosisNCT05868057 · 16 enrolled · China
  7. Aug 9, 2023Phase 3 study in Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early OvulationNCT05994378 · 317 enrolled · China
  8. May 7, 2024Phase 1 study in Assisted ReproductionNCT06408948 · 6 enrolled · China
  9. Apr 22, 2025Phase 1 study in EndometriosisNCT06949124 · 20 enrolled · China
  10. May 6, 2025Phase 1 study in EndometriosisNCT06969664 · 16 enrolled · China

TargetBeta

“GnRH”the company's pipeline, read by Claude · source
“An orally bioavailable gonadotropin-releasing hormone (GnRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration, GnRH antagonist SHR7280 competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland, …”NCIt, read by Claude

Other programs on GNRHR

ProgramCompanyFurthest phaseStudies
LeuprolideruleTakedaphase 439
triptorelinruleIpsenphase 421
GoserelinruleAstraZenecaphase 414
linzagolixruleKissei Pharmaceuticalphase 314
Gonadotropin-Releasing HormoneruleFerring Pharmaceuticalsphase 35
leuprolide mesylateruleforesee-pharmaceuticals-co-ltdphase 33

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06969664Endometriosis · China1CompletedJul 5, 202516
NCT06949124Endometriosis · China1CompletedJun 5, 202520
NCT06408948Assisted Reproduction · China1CompletedJul 6, 20246
NCT05994378Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation · China3CompletedMay 2, 2025317
NCT05868057Endometriosis · China1CompletedJun 9, 202316
NCT05442827Uterine Fibroids With Menorrhagia · China3RecruitingJun 1, 2026357
NCT05082233Female Subjects Undergoing COH in ART to Prevent Early Ovulation · China2CompletedAug 3, 202385
NCT04995042Hormone Sensitive Prostate Cancer · China1CompletedMay 24, 202312
NCT04554043Healthy Subjects · China1CompletedSep 28, 2021118
NCT04417972Endometriosis · China2CompletedMay 14, 2024179

How it is read

Names in the registry

  • “SHR7280 tablets”, 4 entries
  • “SHR7280”, 3 entries
  • “SHR7280;Ganirelix Acetate Injection simulant”, 1 entry
  • “SHR7280 Tablets”, 1 entry
  • “SHR7280 Tablet”, 1 entry

Codes read as this program: SHR7280.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.